Manufacturers present positive data for ibrexafungerup in difficult to treat vaginal candidiasis

In the VANISH-306 study (n=272) a single dose of oral ibrexafungerup (a novel oral glucan synthase inhibitor antifungal under investigation) was superior to placebo for clinical cure at 10 days (defined as complete resolution f all vaginal signs and symptoms – 63.3% vs 44.0%).

Source:

Biospace Inc.